You are here
Cancer drug for children recommended after becoming cost effective for NHS patients
Seriously ill children battling high-risk neuroblastoma, a rare type of cancer that mainly affects children and young people, are to be offered a drug which has potential to extend their lives.
Around 60% of children with high-risk neuroblastoma could be treated with dinutuximab beta.
A National Institute for Health and Care Excellence (NICE) appraisal committee has recommended dinutuximab beta in final draft technology appraisal guidance.
Sign up to receive regular news.